Analyst Ratings For NASDAQ:BPMC – Blueprint Medicines (NASDAQ:BPMC)
Today, Wedbush raised its price target on NASDAQ:BPMC – Blueprint Medicines (NASDAQ:BPMC) to $106.00 per share.
Some recent analyst ratings include
- 2/21/2018-Cowen Reiterated Rating of Buy.
- 11/1/2017-Canaccord Genuity Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:BPMC – Blueprint Medicines (NASDAQ:BPMC)
NASDAQ:BPMC – Blueprint Medicines (NASDAQ:BPMC) has insider ownership of 3.40% and institutional ownership of 97.75%.
- On 3/19/2018 George Demetri, Director, sold 5,492 with an average share price of $100.09 per share and the total transaction amounting to $549,694.28.
- On 3/15/2018 Marion Dorsch, Insider, sold 2,300 with an average share price of $100.07 per share and the total transaction amounting to $230,161.00.
- On 3/2/2018 Jeffrey W Albers, CEO, sold 20,000 with an average share price of $92.57 per share and the total transaction amounting to $1,851,400.00.
- On 2/28/2018 Nicholas Lydon, Director, sold 25,000 with an average share price of $87.89 per share and the total transaction amounting to $2,197,250.00.
- On 2/14/2018 Daniel Lynch, Director, sold 12,500 with an average share price of $80.42 per share and the total transaction amounting to $1,005,250.00.
- On 2/12/2018 Daniel Lynch, Director, sold 17,500 with an average share price of $74.84 per share and the total transaction amounting to $1,309,700.00.
- On 2/12/2018 Kate Haviland, Insider, sold 6,775 with an average share price of $74.93 per share and the total transaction amounting to $507,650.75.
Recent Trading Activity for NASDAQ:BPMC – Blueprint Medicines (NASDAQ:BPMC)
Shares of NASDAQ:BPMC – Blueprint Medicines closed the previous trading session at 86.00 down -12.99 13.12% with 90.91999816894531 shares trading hands.